Evaluation of kidney and liver subacute toxicity induced by Bezalip-Pravastatin-Lopid antihyperlipidaemic compounds in rats

Acute oral toxicity assessment of ethanolic extracts of Antidesma bunius (L.) Spreng fruits in mice

•

In treated mice, mortality during 14-day experimental period was not observed.

•

Bignay extract did not cause behavioral, respiratory and neurologic changes.

•

Liver, kidney, stomach, intestines and esophagus remained intact post Bignay treatment.

•

16 volatile compounds and 10 secondary metabolites were identified.

The aim of the study is to assess the acute oral toxicity of ethanolic extracts of Antidesma bunius (L.) Spreng [Bignay] in ICR mice in accordance to OECD guideline 423. Single doses of Bignay fruit extracts ranging from 500 mg/kg to 2000 mg/kg, as well as a vehicle control, were given orally and monitored for 14 days. We observed that there is no mortality or adverse effects after treatment of mice indicating that Bignay extracts are safe for use in laboratory animals. Behavioral, respiratory, and neurologic changes, as well as changes in body weight, food and water consumption, did not occur during the experimental period. Hematological- (total-red and -white blood cells) and biochemical-profile analysis (alanine transaminase, blood urea nitrogen, and creatinine) remained within normal concentrations in treated mice regardless of sex. The morphology of visceral organs in all treated mice was typical in appearance when stained with H&E. It is assumed that the LD₅₀ is greater than 2000 mg/kg and there is no mortality at the maximum dose used (2000 mg/kg). We have also determined the active components of dried Bignay by headspace GC–MS and by phytochemical analysis of ethanolic Bignay extracts. We have identified 16 compounds by GC–MS and 10 secondary metabolites. In this study, the assessment of extracted Antidesma bunius (L.) Spreng fruits [Bignay] on the value of safety measures in mice is described.

Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats

OBJECTIVE

Fibrates are used as lipid-lowering drugs and are well tolerated as cotreatments when glucose metabolism disturbances are also present. Synthetic glucocorticoids (GCs) are diabetogenic drugs that cause dyslipidemia, dysglycemia, glucose intolerance, and insulin resistance when in excess. Thus, we aimed to describe the potential of bezafibrate in preventing or attenuating the adverse effects of GCs on glucose and lipid homeostasis.

METHODS

Male Wistar rats were treated with high-dose bezafibrate (300 mg/kg, body mass (b.m.)) daily for 28 consecutive days. In the last five days, the rats were also treated with dexamethasone (1 mg/kg, b.m.).

RESULTS

Dexamethasone treatment reduced the body mass gain and food intake, and bezafibrate treatment exerted no impact on these parameters. GC treatment caused an augmentation in fasting and fed glycemia, plasma triacylglycerol and nonesterified fatty acids, and insulinemia, and bezafibrate treatment completely prevented the elevation in plasma triacylglycerol and attenuated all other parameters. Insulin resistance and glucose intolerance induced by GC treatment were abolished and attenuated, respectively, by bezafibrate treatment.

CONCLUSION

High-dose bezafibrate treatment prevents the increase in plasma triacylglycerol and the development of insulin resistance and attenuates glucose intolerance in rats caused by GC treatment, indicating the involvement of dyslipidemia in the GC-induced insulin resistance.